Skip to content
Is the U.S. Holdup of the Oxford/AstraZeneca Vaccine Justified?
Scott Ganz & James C. Capretta /

Is the U.S. Holdup of the Oxford/AstraZeneca Vaccine Justified?

The clamor for its approval is understandable, but there are good reasons to ensure that it is effective enough.
Is the U.S. Holdup of the Oxford/AstraZeneca Vaccine Justified?

The Oxford/AstraZeneca COVID-19 vaccine was once thought to be the frontrunner for U.S. regulatory approval. No longer. Because of safety concerns and questions about the conduct of one of its Phase III trials, it was passed by the mRNA candidates sponsored by the Pfizer/BioNTech tandem and Moderna.

Want to see more of The Dispatch in Google search?

Add Us as a Preferred Source

Scott Ganz is a research fellow in economic policy at the American Enterprise Institute. He is also an associate teaching professor of strategy at the McDonough School of Business at Georgetown University. From 2009 to 2011, he was special assistant to the vice chairman on the Financial Crisis Inquiry Commission.

James C. Capretta is a resident fellow and holds the Milton Friedman chair at the American Enterprise Institute.

More We Think You’d Like

Loading